Hims & Hers Health, Inc. Class A HIMS 深 沪
等待开盘 01-15 09:30:00 美东时间
31.32
-0.880
-2.73%
华盛通- 最 高32.04
- 今 开32.03
- 成交量 1513.10万股
- 最 低 30.75
- 昨 收 32.20
- 总市值 70.78亿
- 52周最高 72.98
- 市盈率 静 58.85
- 换手率 0.01%
- 52周最低 23.97
- 委 比 -81.82%
- 总股本 2.26亿
- 历史最高 72.98
- 量 比 0.81
- 振 幅 4.01%
- 历史最低 2.72
- 每 手 1
- 风险率 10.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Evercore ISI Group Initiates Coverage On Hims & Hers Health with In-Line Rating, Announces Price Target of $33
Evercore ISI Group analyst Mark Mahaney initiates coverage on Hims & Hers Health (NYSE:HIMS) with a In-Line rating and announces Price Target of $33.
01-12 21:33
毛利率75%！这家卖药的公司，如何活成了一家“科技股”？
（来源：美港股观察社） 作者：Gary Alexander 编译：美港股观察社 投资分析 个性化医药公司Hims & Hers Healt...
01-06 18:01
How Do Investors Really Feel About Hims & Hers Health Inc?
Hims & Hers Health Inc's (NYSE:HIMS) short interest as a percent of float h...
2025-12-26 21:00
Hims & Hers brings weight loss program to the U.K.
Hims & Hers (HIMS) is bringing access to its comprehensive weight loss program to the UK. After a detailed clinical assessment by GMC-registered doctors, eligible customers can now access transparent ...
2025-12-10 18:11
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
HIMS Stock Forecast: Barclays Initiates With Buy Rating, Sees Over 20% Upside
Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barc...
2025-12-09 18:23
Hims & Hers to Acquire YourBio; No Financial Terms Disclosed
Acquisition Combines Hims & Hers' Leading Wellness Platform with YourBio's Patented, Virtually Painless Micro-Needle Technology to Redefine the Future of Blood SamplingHims & Hers Health, Inc. (NYSE:HIMS), the
2025-12-03 22:04
Novo Nordisk cuts Wegovy, Ozempic direct-to-user prices to match Eli Lilly’s Zepbound
Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more aggressive push to regain U.S. market share. “Wegovy (semaglutide) injection 0.25 m...
2025-11-17 21:25
Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform
Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite...
2025-11-14 02:49
